These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 19022099)

  • 1. Treatment of HIV lipoatrophy and lipoatrophy of aging with poly-L-lactic acid: a prospective 3-year follow-up study.
    Levy RM; Redbord KP; Hanke CW
    J Am Acad Dermatol; 2008 Dec; 59(6):923-33. PubMed ID: 19022099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of poly-L-lactic acid in HIV lipoatrophy and lipoatrophy of aging.
    Hanke CW; Redbord KP
    J Drugs Dermatol; 2007 Feb; 6(2):123-8. PubMed ID: 17373169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Polylactic acid injections: usefullness for the treatment of facial lipoatrophy in HIV+ patients under tritherapy].
    Piquet M; Brignol L; Chatelain B; Rey D; Ricbourg B; Meyer C
    Rev Stomatol Chir Maxillofac; 2007 Dec; 108(6):496-504. PubMed ID: 17675198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of poly-L-lactic acid (New-Fill®) in the treatment of facial lipoatrophy: a large observational study among HIV-positive patients.
    Duracinsky M; Leclercq P; Herrmann S; Christen MO; Dolivo M; Goujard C; Chassany O
    BMC Infect Dis; 2014 Sep; 14():474. PubMed ID: 25178390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retreatment with injectable poly-l-lactic acid for HIV-associated facial lipoatrophy: 24-month extension of the Blue Pacific study.
    Mest DR; Humble GM
    Dermatol Surg; 2009 Feb; 35 Suppl 1():350-9. PubMed ID: 19207325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Injectable poly-L-lactic acid (Sculptra): technical considerations in soft-tissue contouring.
    Lam SM; Azizzadeh B; Graivier M
    Plast Reconstr Surg; 2006 Sep; 118(3 Suppl):55S-63S. PubMed ID: 16936545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly-L-lactic acid for treating HIV-associated facial lipoatrophy: a review of the clinical studies.
    Barton SE; Engelhard P; Conant M
    Int J STD AIDS; 2006 Jul; 17(7):429-35. PubMed ID: 16820069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy.
    Burgess CM; Quiroga RM
    J Am Acad Dermatol; 2005 Feb; 52(2):233-9. PubMed ID: 15692467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly-L-lactic acid injection for HIV-associated facial lipoatrophy: treatment principles, case studies, and literature review.
    Kates LC; Fitzgerald R
    Aesthet Surg J; 2008; 28(4):397-403. PubMed ID: 19083552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient satisfaction and duration of effect with PLLA: a review of the literature.
    Palm MD; Goldman MP
    J Drugs Dermatol; 2009 Oct; 8(10 Suppl):s15-20. PubMed ID: 19891117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly-L-lactic acid for the treatment of trauma-induced facial lipoatrophy and asymmetry.
    Rendon MI; Keeling J
    Cutis; 2008 Mar; 81(3):218-22. PubMed ID: 18441843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sculptra: the new three-dimensional filler.
    Sherman RN
    Clin Plast Surg; 2006 Oct; 33(4):539-50. PubMed ID: 17085222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sculptra (injectable poly-L-lactic acid).
    Keni SP; Sidle DM
    Facial Plast Surg Clin North Am; 2007 Feb; 15(1):91-7, vii. PubMed ID: 17317560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The face of HIV and AIDS: can we erase the stigma?
    Kavouni A; Catalan J; Brown S; Mandalia S; Barton SE
    AIDS Care; 2008 Apr; 20(4):485-7. PubMed ID: 18449827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duration of correction for human immunodeficiency virus-associated lipoatrophy after retreatment with injectable poly-L-lactic acid.
    Mest DR; Humble GM
    Aesthetic Plast Surg; 2009 Jul; 33(4):654-6. PubMed ID: 18704558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy.
    Moyle GJ; Brown S; Lysakova L; Barton SE
    HIV Med; 2006 Apr; 7(3):181-5. PubMed ID: 16494632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly-L-lactic acid for facial lipoatrophy in HIV.
    El-Beyrouty C; Huang V; Darnold CJ; Clay PG
    Ann Pharmacother; 2006 Sep; 40(9):1602-6. PubMed ID: 16912248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly-L-lactic acid as a facial filler.
    Sterling JB; Hanke CW
    Skin Therapy Lett; 2005 Jun; 10(5):9-11. PubMed ID: 15986083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: the US experience.
    Mest DR; Humble G
    Dermatol Surg; 2006 Nov; 32(11):1336-45. PubMed ID: 17083585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolution of injectable poly-L-lactic acid from the correction of HIV-related facial lipoatrophy to aging-related facial contour deficiencies.
    Burgess C
    J Drugs Dermatol; 2011 Sep; 10(9):1001-6. PubMed ID: 22052268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.